前列腺癌是欧美国家老年男性最常见恶性肿瘤，早期或局限性前列腺癌可通过根治性手术 达到治愈。但随着病程发展，几乎所有初始对雄激素剥夺治疗敏感的前列腺癌患者都将产生激素抵抗， 进展为去势抵抗性前列腺癌（castration⁃ resistant prostate cancer，CRPC）。近年，基于程序性死亡受体⁃1 （PD⁃1）抑制剂帕博利珠单抗（Pembrolizumab）的治疗方案对多种实体瘤效果显著，治疗 CRPC 也取得初步 疗效。本综述旨在总结帕博利珠单抗在CRPC 临床试验中的现状及其存在的问题。 

Prostate cancer（PCa）is most common among American and European elder males. Despite hav⁃ ing the initial effectiveness of radical surgery and androgen deprivation therapy at the preliminary stage，prostate cancer eventually develops into castration⁃resistant prostate cancer（CRPC），which results in a poor prognosis. In recent years，base⁃PD⁃1 inhibitor pembrolizumab has been successfully applied in treating multiple solid tumors， which also has achieved primary efficacy in treating CRPC. This paper summarizes the current status and existing problems of pembrolizumab in the clinical trials of CRPC.